News coverage about Presbia PLC (NASDAQ:LENS) has been trending positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Presbia PLC earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.6392858188911 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Presbia PLC (LENS) traded down 1.85% during trading on Tuesday, reaching $2.65. 2,000 shares of the company’s stock traded hands. Presbia PLC has a 52-week low of $1.86 and a 52-week high of $5.50. The company’s market cap is $44.93 million. The company’s 50-day moving average is $2.39 and its 200 day moving average is $2.87.
Several brokerages have issued reports on LENS. Zacks Investment Research upgraded shares of Presbia PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Presbia PLC in a research report on Tuesday, May 23rd. Finally, Rodman & Renshaw decreased their price target on shares of Presbia PLC from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Presbia PLC presently has a consensus rating of “Hold” and an average target price of $12.00.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/09/positive-media-coverage-somewhat-unlikely-to-affect-presbia-plc-nasdaqlens-share-price.html.
Presbia PLC Company Profile
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.
